BTAI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 35.80%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $1,015,497.13

BioXcel Therapeutics Insider Trading History Chart

BioXcel Therapeutics Share Price & Price History

^$2.59

▼ -0.09 (-3.36%)

As of 04/17/2024 01:00 AM ET

Days: 30 | 90 | 365

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

BioXcel Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/4/2024	Richard I Steinhart	CFO	Sell	1,069	$2.63	$2,811.47	4,765
4/4/2024	Vimal Mehta	CEO	Sell	5,268	$2.62	$13,802.16	43,564
4/4/2024	Vincent O'neill	Insider	Sell	165	$2.62	$432.30	5,408
6/15/2023	Vimal Mehta	CEO	Sell	30,000	$21.54	$646,200.00	39,903
5/22/2023	Vimal Mehta	CEO	Sell	6,500	$25.79	$167,635.00	37,294
5/15/2023	Javier Rodriguez	Insider	Sell	1,785	$27.32	$48,766.20	4,350
5/15/2023	Richard I Steinhart	CFO	Sell	5,000	$27.17	$135,850.00	1,500
4/6/2023	Krishnan Nandabalan	Director	Sell	60,000	$17.32	$1,039,200.00
3/20/2023	Vimal Mehta	CEO	Sell	34,500	$18.32	$632,040.00	15,894
3/15/2023	Frank Yocca	Insider	Sell	985	$19.69	$19,394.65	9,496
3/15/2023	Richard I Steinhart	CFO	Sell	2,084	$19.50	$40,638.00	1,500
1/20/2023	Frank Yocca	Insider	Sell	50,000	$30.00	$1,500,000.00	8,397
1/5/2023	Krishnan Nandabalan	Director	Sell	25,889	$22.34	$578,360.26
12/16/2022	Vimal Mehta	CEO	Sell	30,000	$19.44	$583,200.00	9,957
11/10/2022	Krishnan Nandabalan	Director	Sell	27,450	$15.00	$411,750.00
6/25/2021	Vimal Mehta	CEO	Sell	473,250	$30.83	$14,590,297.50

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

From Paradigm Press | Ad

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

SEC Filings (Institutional Ownership Changes) for BioXcel Therapeutics (NASDAQ:BTAI)

30.68% of BioXcel Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

BioXcel Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/11/2024	Vanguard Group Inc.	1,089,463	$3.21M	0.0%	-10.7%	3.586%
3/1/2024	Goldman Sachs Group Inc.	19,200	$57K	0.0%	-85.6%	0.063%
2/26/2024	Virtu Financial LLC	59,514	$0.18M	0.0%	N/A	0.196%
2/15/2024	Barclays PLC	27,895	$82K	0.0%	+264.4%	0.092%
2/15/2024	Vanguard Group Inc.	1,089,463	$3.21M	0.0%	-10.7%	3.586%
2/14/2024	Pennant Investors LP	83,900	$0.25M	0.1%	N/A	0.276%
2/13/2024	Tower Research Capital LLC TRC	13,832	$41K	0.0%	+239.2%	0.046%
2/13/2024	Goldman Sachs Group Inc.	19,200	$57K	0.0%	-85.6%	0.063%
2/9/2024	Cambridge Investment Research Advisors Inc.	38,050	$0.11M	0.0%	N/A	0.127%
2/7/2024	BNP Paribas Financial Markets	23,424	$69K	0.0%	-69.3%	0.078%
2/6/2024	Charles Schwab Investment Management Inc.	187,510	$0.55M	0.0%	+37.1%	0.626%
2/6/2024	Apollon Wealth Management LLC	10,537	$31K	0.0%	N/A	0.035%
2/2/2024	Truist Financial Corp	10,879	$32K	0.0%	N/A	0.036%
1/23/2024	DAVENPORT & Co LLC	35,385	$0.10M	0.0%	-42.5%	0.118%
12/18/2023	Vanguard Group Inc.	1,220,530	$3.09M	0.0%	+8.1%	4.170%
12/6/2023	Citigroup Inc.	24,336	$62K	0.0%	-59.5%	0.083%
12/1/2023	Wellington Management Group LLP	36,954	$93K	0.0%	-96.9%	0.126%
11/16/2023	Creative Planning	21,224	$54K	0.0%	N/A	0.073%
11/15/2023	Legal & General Group Plc	13,380	$34K	0.0%	-27.5%	0.046%
11/15/2023	Adage Capital Partners GP L.L.C.	200,000	$0.51M	0.0%	-89.8%	0.683%
11/15/2023	Ameriprise Financial Inc.	668,370	$1.69M	0.0%	+91.3%	2.283%
11/13/2023	Northern Trust Corp	225,656	$0.57M	0.0%	-7.6%	0.771%
11/13/2023	FMR LLC	2,700,727	$6.83M	0.0%	-38.2%	9.227%
11/9/2023	Citigroup Inc.	24,336	$62K	0.0%	-59.5%	0.083%
11/9/2023	UBS Group AG	78,604	$0.20M	0.0%	-29.1%	0.269%
11/8/2023	Charles Schwab Investment Management Inc.	136,803	$0.35M	0.0%	-7.7%	0.467%
10/27/2023	Hennion & Walsh Asset Management Inc.	33,940	$86K	0.0%	+89.5%	0.116%
10/24/2023	Bank of New York Mellon Corp	128,022	$0.32M	0.0%	+13.2%	0.437%
10/12/2023	SeaCrest Wealth Management LLC	16,550	$42K	0.0%	-20.0%	0.057%
8/15/2023	Alliancebernstein L.P.	35,880	$0.24M	0.0%	+49.5%	0.123%
8/15/2023	Wells Fargo & Company MN	77,381	$0.52M	0.0%	+62.5%	0.265%
8/15/2023	Knoll Capital Management LLC	30,000	$0.20M	0.2%	N/A	0.103%
8/15/2023	XTX Topco Ltd	16,509	$0.11M	0.0%	N/A	0.057%
8/15/2023	Goldman Sachs Group Inc.	144,046	$0.96M	0.0%	-12.0%	0.494%
8/15/2023	Point72 Asset Management L.P.	241,958	$1.61M	0.0%	N/A	0.830%
8/15/2023	Hudson Bay Capital Management LP	29,300	$0.20M	0.0%	N/A	0.100%
8/14/2023	Tower Research Capital LLC TRC	5,679	$38K	0.0%	+271.4%	0.019%
8/14/2023	State of Wisconsin Investment Board	28,623	$0.19M	0.0%	+19.8%	0.098%
8/14/2023	State Street Corp	2,072,199	$13.80M	0.0%	+17.7%	7.106%
8/14/2023	Nuveen Asset Management LLC	14,808	$99K	0.0%	-75.9%	0.051%
8/14/2023	Driehaus Capital Management LLC	22,220	$0.15M	0.0%	-94.3%	0.076%
8/14/2023	Thrivent Financial for Lutherans	10,000	$64K	0.0%	N/A	0.034%
8/11/2023	Credit Suisse AG	31,456	$0.21M	0.0%	+75.1%	0.108%
8/11/2023	BlackRock Inc.	1,389,229	$9.25M	0.0%	+1.4%	4.764%
8/11/2023	Geode Capital Management LLC	404,650	$2.70M	0.0%	+5.6%	1.388%
8/11/2023	E Fund Management Co. Ltd.	10,628	$71K	0.0%	N/A	0.036%
8/11/2023	JPMorgan Chase & Co.	21,440	$0.14M	0.0%	+24.0%	0.074%
8/11/2023	Northern Trust Corp	244,106	$1.63M	0.0%	+15.3%	0.837%
8/10/2023	Profund Advisors LLC	35,475	$0.24M	0.0%	+29.2%	0.122%
8/10/2023	US Bancorp DE	14,072	$94K	0.0%	+42,542.4%	0.048%
8/10/2023	Charles Schwab Investment Management Inc.	148,174	$0.99M	0.0%	+3.0%	0.508%
8/10/2023	Citigroup Inc.	60,062	$0.40M	0.0%	-49.5%	0.206%
8/9/2023	Dimensional Fund Advisors LP	37,668	$0.25M	0.0%	-38.7%	0.129%
8/9/2023	BNP Paribas Arbitrage SNC	69,994	$0.47M	0.0%	-38.5%	0.240%
8/9/2023	Swiss National Bank	44,200	$0.29M	0.0%	+4.5%	0.152%
8/3/2023	Barclays PLC	100,720	$0.67M	0.0%	+79.8%	0.344%
8/3/2023	Bank of New York Mellon Corp	113,121	$0.75M	0.0%	+46.7%	0.388%
7/25/2023	Raymond James & Associates	18,648	$0.12M	0.0%	+32.7%	0.064%
7/20/2023	DAVENPORT & Co LLC	59,705	$0.40M	0.0%	-25.6%	0.205%
7/19/2023	Artemis Investment Management LLP	895,048	$5.96M	0.1%	-8.8%	3.069%
7/14/2023	SeaCrest Wealth Management LLC	20,700	$0.14M	0.0%	+38.9%	0.071%
5/18/2023	JPMorgan Chase & Co.	17,291	$0.32M	0.0%	+49.1%	0.059%
5/18/2023	New York State Common Retirement Fund	10,885	$0.20M	0.0%	-5.9%	0.037%
5/16/2023	State Street Corp	1,760,683	$32.85M	0.0%	+377.7%	6.038%
5/16/2023	Geode Capital Management LLC	383,129	$7.15M	0.0%	+2.2%	1.314%
5/15/2023	Two Sigma Advisers LP	57,400	$1.07M	0.0%	+95.2%	0.198%
5/15/2023	Two Sigma Investments LP	217,991	$4.07M	0.0%	N/A	0.751%
5/15/2023	Deutsche Bank AG	27,665	$0.52M	0.0%	+14.5%	0.095%
5/12/2023	Renaissance Technologies LLC	94,000	$1.75M	0.0%	N/A	0.324%
5/12/2023	BlackRock Inc.	1,370,688	$25.58M	0.0%	-6.3%	4.725%
5/12/2023	BNP Paribas Arbitrage SNC	113,770	$2.12M	0.0%	+221.6%	0.392%
5/12/2023	AlphaCentric Advisors LLC	40,000	$0.75M	0.5%	-20.0%	0.138%
5/12/2023	Bank of America Corp DE	340,925	$6.36M	0.0%	+193.0%	1.175%
5/12/2023	UBS Group AG	160,289	$2.99M	0.0%	+15.1%	0.553%
5/12/2023	Dimensional Fund Advisors LP	61,432	$1.15M	0.0%	-11.4%	0.212%
5/12/2023	Wellington Management Group LLP	1,334,606	$24.90M	0.0%	N/A	4.601%
5/12/2023	SeaCrest Wealth Management LLC	14,907	$0.28M	0.0%	N/A	0.051%
5/12/2023	Charles Schwab Investment Management Inc.	143,893	$2.69M	0.0%	+0.4%	0.496%
5/12/2023	Profund Advisors LLC	27,462	$0.51M	0.0%	N/A	0.095%
5/11/2023	FMR LLC	4,276,693	$79.80M	0.0%	+1.7%	14.742%
5/11/2023	Rhumbline Advisers	33,490	$0.63M	0.0%	+8.5%	0.115%
5/11/2023	Citigroup Inc.	118,975	$2.22M	0.0%	+19,120.5%	0.410%
5/10/2023	Credit Suisse AG	17,963	$0.34M	0.0%	+28.5%	0.062%
5/10/2023	Tocqueville Asset Management L.P.	37,000	$0.69M	0.0%	-6.1%	0.128%
5/10/2023	Swiss National Bank	42,300	$0.79M	0.0%	-8.6%	0.146%
5/9/2023	Tower Research Capital LLC TRC	1,529	$29K	0.0%	+205.2%	0.005%
5/9/2023	Bank of New York Mellon Corp	77,132	$1.44M	0.0%	+7.2%	0.266%
5/8/2023	Federated Hermes Inc.	61,730	$1.15M	0.0%	N/A	0.213%
5/8/2023	Zurcher Kantonalbank Zurich Cantonalbank	12,103	$0.23M	0.0%	+8.2%	0.042%
5/5/2023	Truist Financial Corp	11,353	$0.21M	0.0%	-4.9%	0.039%
5/5/2023	Artemis Investment Management LLP	981,472	$18.28M	0.2%	-26.4%	3.383%
5/4/2023	Barclays PLC	56,023	$1.05M	0.0%	+990.8%	0.193%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	14,137	$0.26M	0.0%	N/A	0.049%
4/27/2023	DAVENPORT & Co LLC	80,295	$1.50M	0.0%	-48.9%	0.277%
4/21/2023	Capital Investment Advisory Services LLC	17,325	$0.32M	0.0%	N/A	0.060%
4/20/2023	Hennion & Walsh Asset Management Inc.	37,887	$0.71M	0.0%	-3.3%	0.131%
4/14/2023	Raymond James & Associates	14,052	$0.26M	0.0%	-11.8%	0.048%
4/13/2023	Allspring Global Investments Holdings LLC	49,311	$0.92M	0.0%	N/A	0.170%
2/21/2023	Northwestern Mutual Wealth Management Co.	1,740	$37K	0.0%	+411.8%	0.006%
2/17/2023	Truist Financial Corp	11,935	$0.26M	0.0%	-48.8%	0.043%

Data available starting January 2016

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $2.59

$2.58

$2.74

50 Day Range

MA: $2.91

$1.95

$3.75

52 Week Range

Now: $2.59

$1.91

$29.56

Volume

319,910 shs

Average Volume

1,372,707 shs

Market Capitalization

$79.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Who are the company insiders with the largest holdings of BioXcel Therapeutics?: BioXcel Therapeutics' top insider investors include:
Vimal Mehta (CEO)
Frank Yocca (Insider)
Vincent O'neill (Insider)
Richard I Steinhart (CFO)
Javier Rodriguez (Insider)
Krishnan Nandabalan (Director)
Learn More about top insider investors at BioXcel Therapeutics.